文献速递头颈外科咽喉与嗓音

早期扁桃体癌的多模式治疗与生存结局

Multimodality Treatment of Early-Stage Tonsil Cancer.
PubMed 文献 · Otolaryngol Head Neck Surg · 2017-03-07

基于美国国家癌症数据库1998至2011年数据,纳入3247例70岁以下临床I-II期扁桃体鳞状细胞癌患者,比较单纯放疗、单纯手术与手术联合放疗的生存差异。手术联合放疗的5年总生存率最高,倾向评分匹配后结论一致;作者认为以手术为先、再选择辅助治疗可能改善生存,并建议开展前瞻性临床试验。

要点

  • 手术联合放疗的5年总生存率高于单纯手术和单纯放疗。
  • 倾向评分匹配后手术联合放疗的生存优势仍然存在。
  • 以手术为先联合辅助治疗可能改善早期扁桃体癌生存。

核心结论

  • 多模式治疗与早期扁桃体癌最佳生存相关。
  • 在放疗基础上加扁桃体切除术与生存率提高20%相关。
  • 当前指南可能未提供最有效的治疗。
  • 以手术为先、再选择适当辅助治疗可能改善早期扁桃体鳞癌生存。
  • 上述发现值得在前瞻性临床试验中研究。

研究设计与样本

  • 研究类型为美国国家癌症数据库的回顾性队列分析。
  • 纳入1998至2011年数据库记录的70岁以下临床I-II期扁桃体鳞状细胞癌患者。
  • 排除姑息性与非标准治疗。
  • 采用倾向评分匹配,控制肿瘤分期、年龄、种族、合并症、保险状态和诊断年份。
  • 共识别3247例患者;倾向评分匹配亚组2378例。

主要发现

  • 1295例(39.9%)接受放疗,824例(25.4%)接受手术,1128例(34.7%)接受手术+放疗。
  • 手术+放疗的5年总生存率最高(81.1%),其次为手术(67.4%)和放疗(63.4%)(P < .001)。
  • 倾向评分匹配亚组中,5年总生存率为手术+放疗78.8%、手术66.7%、放疗64.5%(P < .001)。
  • 在行扁桃体切除术加择区颈淋巴清扫和/或辅助放疗的患者中,5年总生存率相等(P = .29),且均优于单纯放疗(P < .001)。

关键数值与推荐

  • 5年总生存率:手术+放疗81.1%,手术67.4%,放疗63.4%(P < .001)。
  • 倾向评分匹配亚组5年总生存率:手术+放疗78.8%,手术66.7%,放疗64.5%(P < .001)。
  • 扁桃体切除术加择区颈淋巴清扫和/或辅助放疗者之间5年总生存率相等(P = .29)。
  • 扁桃体切除术加择区颈淋巴清扫和/或辅助放疗者均优于单纯放疗(P < .001)。

临床怎么用

  • 对早期扁桃体鳞癌可考虑以手术为先、再选择适当辅助治疗的模式。
  • 多模式治疗可能带来生存获益,治疗决策需结合患者具体情况。
  • 研究结果提示现有指南推荐可能需要重新评估。

局限性

  • 为回顾性数据库研究,存在选择偏倚等固有局限。
  • 作者指出相关发现需前瞻性临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective Compare survival outcomes between unimodality and multimodality treatments for early-stage tonsil squamous cell carcinoma (SCC). Study Design and Setting Review of the National Cancer Database. Subjects and Methods Patients were selected if they were <70 years old with clinical stage I-II SCC of the tonsil, as documented in the National Cancer Database from 1998 to 2011. Palliative and nonstandard treatments were excluded. Propensity score matching was performed, controlling for tumor stage, age, race, comorbidity, insurance status, and year of diagnosis. Overall survival (OS) was compared with the Kaplan-Meier method and log-rank test. Results We identified 3247 patients. Radiotherapy (RT) was delivered in 1295 patients (39.9%), surgery in 824 (25.4%), and surgery + RT in 1128 (34.7%). Patients treated with surgery + RT had the highest 5-year OS (81.1%), followed by surgery (67.4%) and RT (63.4%; P < .001). In a propensity score-matched subpopulation of 2378 patients, the 5-year OS was 78.8% for surgery + RT, 66.7% for surgery, and 64.5% for RT ( P < .001). Among patients who underwent surgical tonsillectomy plus elective neck dissection and/or adjuvant RT, the 5-year OS was equal ( P = .29), and all were superior to RT alone ( P < .001). Conclusion Multimodality treatment is associated with the greatest survival in early-stage tonsil cancer. The addition of tonsillectomy to RT confers a 20% increase in survival. The current guidelines might not offer the most effective treatment. An up-front surgical approach, followed by appropriately selected adjuvant therapy, may result in improved survival for early-stage tonsil SCC. These findings merit investigation in a prospective clinical trial.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Roden DF, Schreiber D, Givi B, et al. Multimodality Treatment of Early-Stage Tonsil Cancer. Otolaryngol Head Neck Surg. 2017. PMID: 28669307. doi:10.1177/0194599817696290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。